Negara: Armenia
Bahasa: Inggris
Sumber: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
dolutegravir (dolutegravir sodium), lamivudine, tenofovir disoproxil fumarate
Emcure Pharmaceuticals Ltd.
J05AR27
dolutegravir (dolutegravir sodium), lamivudine, tenofovir disoproxil fumarate
50mg+ 300mg+ 300mg
tablets film-coated
(30) in plastic container, (90) in plastic container
Prescription
Registered
2022-12-07
PACKAGE LEAFLET: INFORMATION FOR THE USER VIROPIL 50mg+300mg+300mg; film-coated tablets _dolutegravir+tenofovir disoproxil fumarate + lamivudine _ READ THIS ENTIRE LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist, or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET: 1. What VIROPIL is and what it is used for 2. What you need to know before you take VIROPIL 3. How to take VIROPIL 4. Possible side effects 5. How to store VIROPIL 6. Contents of the pack and other information 1. WHAT VIROPIL IS AND WHAT IT IS USED FOR Viropil is a medicine that contains three active ingredients: dolutegravir, tenofovir disoproxil and lamivudine. Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors. Tenofovir is a nucleotide reverse transcriptase inhibitor, while lamivudine belongs to the group of the nucleoside analogue reverse transcriptase inhibitors. Viropil is used to treat HIV (human immunodeficiency virus) infection in adults and young people who weigh at least 30 kg. Viropil does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. Reducing the amount of virus helps to increase number of white blood cells, called CD4 cells, that are important for fighting infection. Viropil does not work equally well in everybody. Your health care provider will check how well your treatment is working. To control your HIV infection, and to stop your illness from getting worse, you must take all your HIV medicines regularly, unless your health care provider tells you to stop taking any. 2. WHAT YOU NEED TO KNO Baca dokumen lengkapnya
_SUMMARY OF PRODUCT CHARACTERISTICS _ _ _ VIROPIL SUMMARY OF PRODUCT CHARACTERISTICS VIROPIL (DOLUTEGRAVIR 50 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG + LAMIVUDINE 300 MG) _SUMMARY OF PRODUCT CHARACTERISTICS _ _ _ VIROPIL 1. NAME OF THE MEDICINAL PRODUCT Viropil 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DESCRIPTION: White to off white, capsule shaped, film coated tablets, debossed with “HP553” on one side and plain on the other side QUALITATIVE AND QUANTITATIVE COMPOSITION The active ingredients are _dolutegravir, lamivudine and tenofovir disoproxil fumarate_ . Each film coated tablet contains: Dolutegravir Sodium equivalent to Dolutegravir…... 50 mg Lamivudine........ 300 mg Tenofovir Disoproxil Fumarate 300 mg equivalent to Tenofovir Disoproxil.............245 mg For full list of excipients please see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Viropil is indicated for the treatment of human immunodeficiency virus (HIV) infection in adults and adolescents weighing at least 30 kg. Consideration should be given to official treatment guidelines for HIV-1 infection. For use of antiretroviral agents for post-exposure prophylaxis the most recent official guidelines. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Viropil should be prescribed by a health care provider experienced in the management of HIV infection. _ _ _Posology _ _ _ _Adults _ The dose of Viropil is one tablet once daily. _Dose adjustments _ Where discontinuation of therapy with one of the components of Viropil is indicated or where dose modification is necessary, separate preparations of dolutegravir, lamivudine and tenofovir disoproxil should be used. Please refer to the individual product information for these medicinal products. _SUMMARY OF PRODUCT CHARACTERISTICS _ _ _ VIROPIL When the patient’s HIV-1 infection is known or suspected to be resistant to integrase inhibitors, additional doses of dolutegravir are necessary. Please refer to the product information of dolutegravir for Baca dokumen lengkapnya